REG - Allergy Therapeutics - Annual Report and AGM Notification
RNS Number : 4127OAllergy Therapeutics PLC07 October 20217 October 2021
Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")
ANNUAL FINANCIAL REPORT 2021 AND NOTICE OF 2021 ANNUAL GENERAL MEETING
Allergy Therapeutics plc has today published the following documents:
· Annual Report and Accounts for the year ended 30 June 2021 ("Annual Report"); and
· Notice of 2021 Annual General Meeting ("Notice of Meeting");
Each of these documents is available electronically on the Company's website at www.allergytherapeutics.com
A hard copy of the Annual Report and Notice of Meeting has been posted to shareholders on 6 October 2021.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Emma Earl / Mark Rogers, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology group focussed on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional fourteen countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which has achieved 10% compound annual growth since formation, employs c.500 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDMSCFLFVEIELDIIL
Recent news on Allergy Therapeutics
See all newsREG - Allergy Therapeutics - Director Resignation
AnnouncementREG - Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023
AnnouncementREG - Allergy Therapeutics - Update on funding
AnnouncementREG - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
AnnouncementRCS - Allergy Therapeutics - VLP Peanut PROTECT Trial Update
Announcement